Keyphrases
Acute Lymphoblastic Leukemia
29%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
77%
Allogeneic Transplantation
15%
Chemotherapy
25%
Childhood Cancer Survivor Study
53%
Childhood Cancer Survivors
53%
Children's Oncology Group
41%
Cisplatin
17%
Confidence Interval
47%
Consensus Conference
15%
Event-free Survival
25%
Graft-versus-host Disease (GvHD)
62%
Haematopoietic Stem Cell Transplant Recipients
16%
Hearing Impairment
28%
Hematopoietic Cell Transplantation
66%
Hematopoietic Stem Cell Transplantation
34%
Late Effects
54%
Lung Transplantation
18%
Lymphoblastic Lymphoma
15%
Marrow Transplantation
32%
Methotrexate
25%
Nashville
15%
NCCN Guidelines
20%
Newly Diagnosed
19%
Non-Hodgkin Lymphoma
26%
Odds Ratio
25%
Older Adults
35%
Oncology
18%
Overall Survival
28%
Pediatric
71%
Pediatric Cancer Patients
26%
Pediatric Oncology
23%
Pediatric Patients
37%
Post-transplant Lymphoproliferative Disorder
54%
Preparative Regimen
17%
Quality of Life
22%
Reduced Intensity
15%
Reduced-intensity Conditioning
34%
Retinoblastoma
20%
Risk Factors
42%
Solid Cancer
15%
Solid Organ Transplantation
15%
Stem Cell Transplantation
22%
Sudden Sensorineural Hearing Loss (SSNHL)
15%
Survivors
100%
Total Body Irradiation
21%
Transplantation
23%
Unrelated Donor
20%
Young Adult Oncology
30%
Young Adult Patients
20%
Medicine and Dentistry
Acute Leukemia
20%
Acute Lymphoblastic Leukemia
42%
Acute Myeloid Leukemia
13%
Adolescence
81%
Allograft
24%
Cell Transplantation
78%
Central Nervous System
11%
Childhood Cancer
91%
Chronic Graft Versus Host Disease
18%
Diseases
56%
Drug Megadose
15%
Epstein Barr Virus
14%
Event Free Survival
21%
Graft Versus Host Reaction
25%
Hearing Impairment
12%
Hematologic Malignancy
15%
Hematopoietic Cell
83%
Hematopoietic Stem Cell Transplantation
40%
Immunosuppressive Treatment
14%
Infection
11%
Late Effect
42%
Leukemia
16%
Long Term Survival
11%
Lung Transplantation
17%
Lymphoblastic Lymphoma
17%
Lymphoma Cell
15%
Malignant Neoplasm
37%
Methotrexate
35%
Myelodysplastic Syndrome
14%
Neoplasm
19%
Non-Hodgkin Lymphoma
23%
Odds Ratio
19%
Oncology
73%
Overall Survival
29%
Pediatric Cancer
11%
Pediatrics
91%
Pediatrics Patient
29%
Posttransplant Lymphoproliferative Disease
41%
Prevalence
32%
Quality of Life
23%
Radiation Therapy
17%
Reduced Intensity Conditioning
25%
Retinoblastoma
15%
Rituximab
12%
Sickle-Cell Disease
15%
Solid Malignant Neoplasm
18%
Solid Organ Transplantation
15%
T Cell
13%
Transplantation
66%
Whole Body Radiation
18%